Orgenesis INC. (ORGS) — SEC Filings

Overview

Orgenesis INC. (ORGS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: Orgenesis Inc. (ORGS) is a global biotech company focused on making cell and gene therapies (CGTs) affordable and accessible through its decentralized cell processing (DCP) platform. The company reported a market value of $7,649,760 as of June 30, 2024, with 9,799,538 shares outstanding as of March

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 4 bearish, 35 neutral, 2 mixed. The dominant filing sentiment for Orgenesis INC. is neutral.

Filing Type Overview

Orgenesis INC. (ORGS) has filed 2 10-K, 33 8-K, 2 SC 13G/A, 3 10-Q, 1 DEF 14A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• Orgenesis Shifts to OTC, Eyes Decentralized Cell Therapy Growth — 10-K · Mar 26, 2026 Risk: high
  Orgenesis Inc. (ORGS) is a global biotech company focused on making cell and gene therapies (CGTs) affordable and accessible through its decentralized cell proc
• Orgenesis Inc. Files 8-K on Material Agreement — 8-K · Sep 16, 2025 Risk: medium
  On September 16, 2025, Orgenesis Inc. filed an 8-K report detailing a material definitive agreement and the creation of a direct financial obligation. The filin
• Orgenesis Inc. Files 8-K with Director/Officer Changes & Exhibits — 8-K · Aug 25, 2025 Risk: low
  Orgenesis Inc. filed an 8-K on August 25, 2025, reporting changes in its board of directors and officers, and also filed financial statements and exhibits. The
• Orgenesis Inc. Files 8-K: Director/Officer Changes & Financials — 8-K · Aug 19, 2025 Risk: low
  Orgenesis Inc. filed an 8-K on August 19, 2025, reporting changes in its board of directors and officers, as well as compensatory arrangements. The filing also
• Orgenesis Inc. Files 8-K Report — 8-K · Aug 1, 2025 Risk: low
  Orgenesis Inc. filed an 8-K report on August 1, 2025, primarily to disclose other events and financial statements/exhibits. The filing does not contain specific
• Orgenesis Inc. Faces Delisting Notice — 8-K · Jun 6, 2025 Risk: high
  Orgenesis Inc. filed an 8-K on June 6, 2025, to report a notice of delisting or failure to satisfy continued listing rules. The company, incorporated in Nevada
• Orgenesis Inc. Files 8-K Report — 8-K · Apr 22, 2025 Risk: medium
  On April 22, 2025, Orgenesis Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. Specific details regarding the nat
• Orgenesis Inc. Completes Acquisition, Signs Key Agreement — 8-K · Mar 6, 2025 Risk: medium
  Orgenesis Inc. announced on February 28, 2025, the completion of an acquisition, marking a significant event for the company. The filing also indicates the entr
• Orgenesis Inc. Files 8-K for Material Agreement — 8-K · Jan 28, 2025 Risk: low
  On January 28, 2025, Orgenesis Inc. filed an 8-K report to disclose a material definitive agreement and financial statements. The company, incorporated in Nevad
• Orgenesis Inc. Reports Board and Officer Changes — 8-K · Dec 27, 2024 Risk: low
  Orgenesis Inc. announced on December 24, 2024, changes in its board of directors and executive compensation. Specifically, the company elected new directors and
• SC 13G/A Filing — SC 13G/A · Dec 4, 2024
• Orgenesis Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 13, 2024 Risk: medium
  Orgenesis Inc. filed its quarterly report for the period ending September 30, 2024. The company, incorporated in Nevada and operating in Pharmaceutical Preparat
• Orgenesis Inc. Reports Material Definitive Agreement & Financial Obligations — 8-K · Nov 5, 2024 Risk: medium
  On October 31, 2024, Orgenesis Inc. entered into a material definitive agreement related to its financial obligations. The company also reported on the creation
• Orgenesis Inc. Files 8-K: Director/Officer Changes & Financials — 8-K · Nov 1, 2024 Risk: medium
  Orgenesis Inc. filed an 8-K on October 28, 2024, reporting changes in its board of directors and certain officers, as well as compensatory arrangements. The fil
• Orgenesis Inc. Elects New Directors to Board — 8-K · Oct 23, 2024 Risk: low
  Orgenesis Inc. announced on October 23, 2024, a change in its board of directors. Specifically, the company elected two new directors, Dr. David J. Glick and Mr
• Orgenesis Inc. Faces Delisting Notice — 8-K · Oct 17, 2024 Risk: high
  Orgenesis Inc. filed an 8-K on October 17, 2024, to report a notice of delisting or failure to satisfy continued listing rules. The company, incorporated in Nev
• Orgenesis Inc. Files 8-K on Security Holder Rights — 8-K · Sep 23, 2024 Risk: medium
  Orgenesis Inc. filed an 8-K on September 23, 2024, reporting material modifications to the rights of security holders and amendments to its articles of incorpor
• Orgenesis Inc. Files 8-K with Financials — 8-K · Aug 29, 2024 Risk: medium
  Orgenesis Inc. filed an 8-K on August 29, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's ope
• Orgenesis Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 26, 2024 Risk: medium
  On August 21, 2024, Orgenesis Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregister
• Orgenesis Inc. Files 8-K on Equity Sales and Financials — 8-K · Aug 14, 2024 Risk: medium
  On August 9, 2024, Orgenesis Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The filing also includes fina
• Orgenesis Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 8, 2024 Risk: medium
  Orgenesis Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial position and operational activities. Specific fina
• Orgenesis Inc. Completes Acquisition — 8-K · Jul 12, 2024 Risk: medium
  Orgenesis Inc. announced on July 10, 2024, the completion of an acquisition. The company entered into a material definitive agreement related to this transactio
• Orgenesis Inc. Reports Board and Executive Compensation Changes — 8-K · Jul 9, 2024 Risk: medium
  Orgenesis Inc. announced on July 3, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the dep
• Orgenesis Inc. Enters Material Definitive Agreement — 8-K · Jul 8, 2024 Risk: medium
  On July 3, 2024, Orgenesis Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Nevada with i
• Orgenesis Inc. Files 8-K on Officer/Director Changes & Voting Matters — 8-K · Jun 27, 2024 Risk: medium
  Orgenesis Inc. filed an 8-K on June 27, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain
• Orgenesis Inc. Faces Delisting or Listing Transfer — 8-K · Jun 11, 2024 Risk: high
  Orgenesis Inc. filed an 8-K on June 11, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The filing indicates a potential t
• Orgenesis Inc. Files Current Report — 8-K · May 31, 2024 Risk: low
  Orgenesis Inc. (ORGS) reported on May 31, 2024, that its common stock is traded on The Nasdaq Capital Market. The company is incorporated in Nevada and has its
• Orgenesis Inc. Files 8-K with Material Agreements — 8-K · May 23, 2024 Risk: medium
  On May 21, 2024, Orgenesis Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed fin
• Orgenesis Inc. Files Q1 2024 10-Q Report — 10-Q · May 20, 2024 Risk: medium
  Orgenesis Inc. filed its Q1 2024 10-Q report on May 20, 2024, covering the period ending March 31, 2024. The company, operating in the Pharmaceutical Preparatio
• Orgenesis Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · May 6, 2024 Risk: low
  Orgenesis Inc. (ORGS) filed a Proxy Statement (DEF 14A) with the SEC on May 6, 2024. The 2024 annual meeting of Orgenesis Inc. stockholders will be held virtual
• Orgenesis Inc. Faces Delisting Concerns — 8-K · Apr 19, 2024 Risk: high
  Orgenesis Inc. filed an 8-K on April 19, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was o
• Orgenesis Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 15, 2024 Risk:
  Orgenesis Inc. (ORGS) filed a Annual Report (10-K) with the SEC on April 15, 2024. Orgenesis Inc. filed its 10-K report for the fiscal year ending December 31,
• Orgenesis Inc. Files 8-K for Material Agreement — 8-K · Apr 11, 2024 Risk: medium
  Orgenesis Inc. entered into a material definitive agreement on April 5, 2024. The filing also includes financial statements and exhibits related to this agreeme
• Orgenesis Inc. Files 8-K Reporting Other Events — 8-K · Mar 27, 2024 Risk: medium
  Orgenesis Inc. filed an 8-K on March 27, 2024, to report other events. The filing does not contain specific details about the nature of these events, the dollar
• Orgenesis Inc. Files Form 8-K — 8-K · Mar 7, 2024 Risk: medium
  Orgenesis Inc. announced on March 3, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
• Orgenesis Inc. Files 8-K for Material Agreement — 8-K · Mar 1, 2024 Risk: medium
  Orgenesis Inc. filed an 8-K on March 1, 2024, reporting a material definitive agreement entered into on February 26, 2024. The filing also includes financial st
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Orgenesis Enters Material Definitive Agreement on Jan 29 — 8-K · Jan 31, 2024
  Orgenesis Inc. (ORGS) filed an 8-K on January 31, 2024, reporting a material definitive agreement entered into on January 29, 2024. This filing indicates a sign
• Orgenesis Enters Material Definitive Agreement on Jan 18 — 8-K · Jan 24, 2024
  Orgenesis Inc. (ORGS) filed an 8-K on January 24, 2024, reporting an "Entry into a Material Definitive Agreement" that occurred on January 18, 2024. This indica
• Orgenesis Files 8-K on Material Definitive Agreement; Details Undisclosed — 8-K · Jan 22, 2024
  Orgenesis Inc. (ORGS) filed an 8-K on January 22, 2024, reporting an "Entry into a Material Definitive Agreement" that occurred on January 16, 2024. While the f
• Orgenesis Reports Material Agreement, New Debt, Unregistered Equity Sales — 8-K · Jan 5, 2024
  Orgenesis Inc. filed an 8-K on January 5, 2024, reporting events from January 1, 2024, related to entering a material definitive agreement, creating a direct fi

Risk Profile

Risk Assessment: Of ORGS's 34 recent filings, 5 were flagged as high-risk, 21 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Orgenesis INC.'s most recent 10-K filing (Mar 26, 2026):

• Revenue: $1,200,000
• Net Income: -$19,598,603
• EPS: -$2.00
• Debt-to-Equity: N/A
• Cash Position: $1,000,000
• Operating Margin: -1633.2%
• Total Assets: $10,000,000
• Total Debt: $5,000,000

Key Executives

• Dr. David J. Glick
• Mr. David M. Glick

Industry Context

The global cell and gene therapy (CGT) market is experiencing rapid growth, evidenced by a significant increase in approved therapies and drugs in development, with CGTs representing 19.4% of drugs in development. However, the production of these 'living drugs' remains complex, costly, and logistically challenging, primarily relying on traditional centralized manufacturing. This creates a substantial market opportunity for innovative solutions like decentralized processing.

Top Tags

material-agreement (11) · corporate-governance (6) · equity-sale (5) · financial-obligation (4) · filing (4) · delisting (4) · financials (4) · financial-reporting (3) · 8-K (3) · disclosure (3)

Key Numbers

• Aggregate market value of common stock held by non-affiliates: $7,649,760 — as of June 30, 2024, indicating a small market capitalization
• Shares of common stock outstanding: 9,799,538 — as of March 26, 2026
• Reverse stock split ratio: 1-for-10 — implemented on September 20, 2024, to adjust share price and count
• Active clinical trials in global CGT market: 1894 — as per ARM 2024 State of the Industry Briefing H1, showing market growth
• CGTs approved by the FDA: 7 — in 2023, highlighting a breakthrough year for the industry
• Patients treated with CAR-T8-TOR platform: 200 — in Asia, demonstrating platform adoption
• Patients treated with Icellator2 platform: 1,750 — in the rest of the world across eleven indications, showcasing global reach
• Pediatric and adult patients treated with TROJAN Platform: 16 — in Europe for relapsed or refractory solid tumors
• Percentage of drugs in development that are CGTs: 19.4% — out of 21,292 drugs, up from 12% in 2020, indicating significant industry shift
• Acquisition cost of Kite Pharma by Gilead Sciences: $11.9 billion — illustrating high valuation of CGT companies
• Reporting Period: Q3 2024 — Covers the third quarter of the fiscal year ending December 31, 2024.
• Report Date: 2024-09-30 — The end date for the financial information presented in the report.
• Filing Date: 2024-11-13 — The date the report was officially submitted to the SEC.
• Directors to be elected: 6 — Number of persons to be elected to the Board of Directors at the annual meeting.
• Annual Meeting Year: 2024 — Year of the Orgenesis Inc. annual meeting of stockholders.

Related Companies

OGN · OGNS

Frequently Asked Questions